Health Care & Life Sciences » Pharmaceuticals | Kaken Pharmaceutical Co. Ltd.

Kaken Pharmaceutical Co. Ltd. | Income Statement

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Sales/Revenue
88,946
93,889
109,730
101,991
98,432
94,167
Cost of Goods Sold (COGS) incl. D&A
45,440
45,060
47,885
44,814
42,609
40,590
Gross Income
43,506
48,829
61,845
57,177
55,823
53,577
SG&A Expense
27,558
28,204
26,187
26,470
28,326
28,985
EBIT
15,951
20,631
35,146
30,707
27,497
24,592
Unusual Expense
524
1,049
8
-
-
10
Non Operating Income/Expense
184
951
167
402
203
353
Interest Expense
44
28
27
21
16
17
Pretax Income
15,496
18,611
35,292
31,092
27,686
24,922
Income Tax
5,761
6,489
14,149
9,075
8,643
7,147
Consolidated Net Income
9,735
12,122
21,143
22,017
19,043
17,775
Net Income
9,735
12,122
21,143
22,017
19,043
17,775
Net Income After Extraordinaries
9,735
12,122
21,143
22,017
19,043
17,775
Net Income Available to Common
9,735
12,122
21,143
22,017
19,043
17,775
EPS (Basic)
228.28
290.88
510.54
536.71
470.55
445.78
Basic Shares Outstanding
43
42
41
41
40
40
EPS (Diluted)
228.27
290.88
510.54
536.71
470.55
445.78
Diluted Shares Outstanding
43
42
41
41
40
40
EBITDA
18,560
23,031
37,388
32,644
29,621
27,191
Other Operating Expense
3
6
512
-
-
-
Non-Operating Interest Income
8
8
14
4
5
6

About Kaken Pharmaceutical Co.

View Profile
Address
2-28-8 Honkomagome
Tokyo Tokyo 113
Japan
Employees -
Website http://www.kaken.co.jp
Updated 07/08/2019
Kaken Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products, medical devices, agrochemicals, and animal health products in Japan. Its operations are carried out through the following business divisions: Pharmaceuticals and Medical Devices, Agrochemicals and Animal Health Products, Overseas Activity, Research & Development, and Licensing Opportunities. The Pharmaceuticals and Medical Devices division offers artz(anti-osteoarthritis), clenafin (topical onychomycosis treatment product), seprafilm (anti-adhesive absorbent barrier), lipidil (anti-hyperlipidemia product), fiblast spray (wound-healing product), mentax (anti-trichophyton product) and generic drugs.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.